Completely agree the company should take the penalty. We need to see the data. It's too easy for the DSMB to say, "Nice work. Complete the trial." Then we're sitting ducks for the next three months while we struggle to enroll the remaining 160 patients and get the data. REGN, HGEN, RLFTF, Lilly, etc. will likely have approved drugs by then.
Take the penalty. Especially in the (probably unlikely) event that the data is not as good as we hope. In that case, the wise business decision is to shut it down and allocate funds to other trials.